Lack of benefit of intravenous synthetic human secretin in the treatment of autism.

@article{Molloy2002LackOB,
  title={Lack of benefit of intravenous synthetic human secretin in the treatment of autism.},
  author={Cynthia A. Molloy and Patricia Manning-Courtney and Susan Swayne and J. N. Bean and Jennifer M Brown and Donna S. Murray and Anne M Kinsman and Mark Brasington and Charles D. Ulrich},
  journal={Journal of autism and developmental disorders},
  year={2002},
  volume={32 6},
  pages={545-51}
}
The objective of this study was to determine if an intravenous infusion of synthetic human secretin improves language and behavioral symptoms in children with autism. Forty-two children with the diagnosis of autism were randomized to one of two groups in this double-blind cross-over trial. One group received 2 IU/kg of intravenous synthetic human secretin at the first visit, followed by an equal volume of intravenous saline placebo at week 6. The other group received treatments in the reverse… CONTINUE READING